Relafen 750, a advanced formulation of naproxen, represents the intriguing case from our biochemical pharmacy view. Its mechanism of action, primarily involving blocking of cyclooxygenase enzymes – COX-1 and COX-2 – contributes to significant reduction in prostaglandin production. Considering our